Page last updated: 2024-08-26

fulvestrant and Cancer of Ovary

fulvestrant has been researched along with Cancer of Ovary in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (11.54)	18.2507
2000's	8 (30.77)	29.6817
2010's	13 (50.00)	24.3611
2020's	2 (7.69)	2.80

Authors

Authors	Studies
Frydman, V; Gayer, B; Katzburg, S; Kohen, F; Kulik, T; Limor, R; Nevo, N; Sharon, O; Somjen, D; Stern, N	1
Bearss, NR; Bhatnagar, D; Boue, SM; Burow, ME; Cleveland, TE; Erhardt, PW; Khupse, RS; Reese, MD; Sarver, JG; Trendel, JA; Wiese, TE	1
Hossain, MM; Ishibashi, T; Ishikawa, M; Kanno, K; Kyo, S; Nakayama, K; Nakayama, S; Otsuki, Y; Razia, S; Sato, S; Shanta, K; Yamashita, H	1
Bussies, PL; Schlumbrecht, M	1
Argenta, PA; Faratian, D; Geller, MA; Harrison, D; Kay, C; Langdon, SP; Sueblinvong, T; Um, I	1
Chang, WC; Chang, YY; Chen, LC; Chen, LM; Chung, WM; Hung, YC; Lin, TY; Ma, WL; Wu, LY	1
Fu, J; Gou, W; Han, X; Li, L; Li, X; Yang, T; Zhang, Y	1
Han, A; Kim, K; Lokich, E; Moore, RG; Romano, N; Singh, RK; Yano, N	1
Choi, KC; Go, RE; Kim, CW	1
Besser, AH; Brafford, P; El-Ashry, D; Gao, W; Gu, M; Hew, KE; Ince, TA; Lu, Y; Miller, PC; Mills, GB; Simpkins, F; Slingerland, JM; Sun, J; Wei, Z; Zhang, G	1
Andersen, CL; Boisen, MM; Chandran, U; Christie, A; Edwards, RP; Elishaev, E; Haluska, P; Lee, AV; Luthra, S; Ma, T; Mantia-Smaldone, GM; McLean, K; Odunsi, K; Oesterreich, S; Park, Y; Sikora, MJ; Tseng, G	1
Argenta, PA; Carson, LF; Downs, LS; Geller, MA; Ghebre, R; Jonson, AL; Judson, PL; Thomas, SG	1
Goerse, R; Haselberger, M; Konwisorz, A; Ortmann, O; Springwald, A; Treeck, O	1
Choi, JH; Lee, KT; Leung, PC	1
Badia, E; Balaguer, P; Busson, M; Cavailles, V; Docquier, A; Lapierre, M; Pujol, P	1
Azzam, D; da Silva, T; Gilbert, CA; Hevia-Paez, P; Ince, TA; Levin, ER; Lu, Y; Mills, GB; Pedram, A; Rabinovich, B; Reis, IM; Simpkins, F; Slingerland, JM; Sun, J; Ullmer, W; Verhaak, RG; Xu, XX; Yang, JY	1
Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L	1
Hall, JM; Korach, KS	1
Kelley, KM; Ratnam, M; Rowan, BG	1
Haldar, C; Ortmann, O; Treeck, O	1
Adachi, S; Arima, T; Asanoma, K; Kato, K; Kinoshita, K; Ohgami, T; Suga, S; Wake, N; Yamaguchi, S; Yamayoshi, A	1
Crew, AJ; Langdon, SP; Miller, WR; Muir, M; Ritchie, AA; Smyth, JF; Wakeling, A	1
Battaglia, A; Benedetti Panici, P; Cicchillitti, L; Ercoli, A; Fattorossi, A; Malorni, W; Mancuso, S; Rainaldi, G; Raspaglio, G; Scambia, G	1
Afshari, CA; Annab, LA; Barrett, JC; Risinger, JI; Romagnolo, D; Terry, LA; Thompson, TE	1
Alimonti, A; Battaglia, A; Caroli, S; Ercoli, A; Fattorossi, A; Mancuso, S; Petrucci, F; Raspaglio, G; Scambia, G	1
Anderson, JJ; Chen, X	1

Trials

2 trial(s) available for fulvestrant and Cancer of Ovary

Article	Year
Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecologic oncology, 2013, Volume: 131, Issue:2 Topics: Antineoplastic Agents, Hormonal; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tissue Array Analysis	2013
A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecologic oncology, 2009, Volume: 113, Issue:2 Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bone and Bones; Collagen Type I; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peptides	2009

Other Studies

24 other study(ies) available for fulvestrant and Cancer of Ovary

Article	Year
Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Boc-hexylenediamine. Journal of medicinal chemistry, 2007, Dec-13, Volume: 50, Issue:25 Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Cell Line, Tumor; Chromones; Colonic Neoplasms; DNA; Drug Interactions; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Isoflavones; Male; Mice; Mice, Nude; Muscle, Smooth, Vascular; Neoplasm Transplantation; Ovarian Neoplasms; Ovary; Prostate; RNA, Messenger; Transplantation, Heterologous	2007
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I. Journal of medicinal chemistry, 2011, May-26, Volume: 54, Issue:10 Topics: Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Models, Chemical; Ovarian Neoplasms; Prostatic Neoplasms; Pterocarpans; Receptors, Estrogen; Stereoisomerism	2011
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. Current oncology (Toronto, Ont.), 2022, 06-01, Volume: 29, Issue:6 Topics: Cell Line; Cystadenocarcinoma, Serous; Female; Fulvestrant; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Receptors, Estrogen	2022
Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer. The oncologist, 2020, Volume: 25, Issue:7 Topics: Female; Fulvestrant; Humans; Ovarian Neoplasms; Pyridones; Pyrimidinones	2020
Non-genomic estrogen/estrogen receptor α promotes cellular malignancy of immature ovarian teratoma in vitro. Journal of cellular physiology, 2014, Volume: 229, Issue:6 Topics: Cell Line, Tumor; Cell Movement; Estradiol; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Ovarian Neoplasms; Phosphorylation; Teratoma; Tissue Culture Techniques; Tumor Stem Cell Assay	2014
An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade. Oncology reports, 2014, Volume: 32, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzodioxoles; Cell Cycle; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Ovarian Neoplasms; Quinazolines; src-Family Kinases; Survival Analysis	2014
HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Scientific reports, 2014, Jun-30, Volume: 4 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; Karyopherins; Microscopy, Confocal; Ovarian Neoplasms; Protein Transport; Proteins; Tamoxifen; Tumor Cells, Cultured; WAP Four-Disulfide Core Domain Protein 2	2014
Effect of fenhexamid and cyprodinil on the expression of cell cycle- and metastasis-related genes via an estrogen receptor-dependent pathway in cellular and xenografted ovarian cancer models. Toxicology and applied pharmacology, 2015, Nov-15, Volume: 289, Issue:1 Topics: Amides; Animals; Cathepsin D; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oncogene Proteins; Ovarian Neoplasms; Pyrimidines; Receptors, Estrogen	2015
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Feb-15, Volume: 22, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Receptors, Estrogen; Transcriptome; Treatment Outcome; Xenograft Model Antitumor Assays	2016
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jul-15, Volume: 23, Issue:14 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice; Ovarian Neoplasms; Xenograft Model Antitumor Assays	2017
Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells. Endocrine-related cancer, 2010, Volume: 17, Issue:1 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Ovarian Neoplasms; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured	2010
Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. Carcinogenesis, 2011, Volume: 32, Issue:4 Topics: Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Leptin; Ovarian Neoplasms; Signal Transduction; STAT3 Transcription Factor	2011
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:1-2 Topics: Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation; Humans; Ovarian Neoplasms; RNA, Messenger; Signal Transduction; Tamoxifen	2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-01, Volume: 18, Issue:21 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Ovarian Neoplasms; Protein Binding; Protein Transport; Quinazolines; Receptors, Estrogen; src-Family Kinases; Xenograft Model Antitumor Assays	2012
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma. PloS one, 2013, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2013
Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:5 Topics: Breast Neoplasms; Carcinoma; Cell Division; Chemokine CXCL12; Chemokines, CXC; Cycloheximide; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mitogens; Ovarian Neoplasms; Protein Isoforms; Protein Synthesis Inhibitors; Receptors, CXCR4; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured	2003
Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer research, 2003, Jun-01, Volume: 63, Issue:11 Topics: Carrier Proteins; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Folate Receptors, GPI-Anchored; Fulvestrant; Gene Silencing; HeLa Cells; Humans; Ovarian Neoplasms; Promoter Regions, Genetic; Receptors, Cell Surface; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Tumor Cells, Cultured	2003
Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncology reports, 2006, Volume: 15, Issue:1 Topics: Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Melatonin; Ovarian Neoplasms; Receptor, Melatonin, MT1; Signal Transduction; Tamoxifen; Up-Regulation	2006
An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecologic oncology, 2007, Volume: 105, Issue:2 Topics: Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Ovarian Neoplasms; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Tumor Suppressor Protein p53	2007
Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:5 Topics: Adenocarcinoma; Animals; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Polyunsaturated Alkamides; Receptors, Estrogen; Tamoxifen; Transplantation, Heterologous; Tumor Cells, Cultured	1994
Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line. International journal of cancer, 1998, Mar-30, Volume: 76, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Division; Cell Nucleus; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ovarian Neoplasms; Receptors, Estrogen; Tamoxifen; Time Factors; Tumor Cells, Cultured	1998
Estrogen upregulation of BRCA1 expression with no effect on localization. Molecular carcinogenesis, 1998, Volume: 22, Issue:2 Topics: Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Receptors, Estrogen; RNA, Messenger; Stimulation, Chemical; Tumor Cells, Cultured; Up-Regulation	1998
Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction. International journal of cancer, 2000, Jan-01, Volume: 85, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Division; Chromatin; Cisplatin; DNA Adducts; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Electrophoresis, Agar Gel; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ovarian Neoplasms; Tumor Cells, Cultured	2000
Isoflavones inhibit proliferation of ovarian cancer cells in vitro via an estrogen receptor-dependent pathway. Nutrition and cancer, 2001, Volume: 41, Issue:1-2 Topics: Cell Division; Cell Survival; DNA; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression; Genistein; Glycine max; Humans; Interleukin-6; Isoflavones; Ovarian Neoplasms; Receptors, Estrogen; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured	2001